 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1136921
Philippines Pharmaceuticals and Healthcare Report Q1 2010
|
Description: |
Business Monitor International's Philippines Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on the Philippines' pharmaceuticals and healthcare industry.
Valued at PHP116bn (US$2.6bn) in 2008, the Philippines pharmaceutical market is expected to grow by 7.6% in local currency terms during 2009. This rate of expansion is lower than that seen in recent years – the 2003-08 CAGR was 14.96% – because of a deteriorating macroeconomic environment. However, as the economic climate improves, the pace of growth is expected to quicken again due to the significant unmet need for healthcare among the country’s 90mn population. Over the five years to 2014, BMI forecasts that pharmaceutical expenditure should increase by 8.8% in local currency terms, reaching PHP191bn (US$4.6bn) in 2014. The publisher's 10-year forecast projects that the market should reach a value of PHP281bn (US$7.8bn) in 2019.
Voluntary price cuts were implemented in August 2009. Producers acted in response to Executive Order (EO) No. 821 which was signed by President Gloria Macapagal-Arroyo. The decree mandated that five of the most vital drugs – amlodipine, atorvastatin, azithromycin, cytarabine and doxorubicin – be subject to a halving in price.
The five medicines covered by EO No. 821 were chosen because they were essential to maintaining health; without generic equivalents; priced four to five times higher than counterparts abroad; and targeted diseases with high burdens, such as hypertension, high cholesterol, infections and cancer. Resources devoted to drug regulation are likely to increase following the establishment of the Philippines Food and Drugs Administration (FDA), which will replace the Bureau of Food and Drugs (BFAD). The FDA will be permitted to retain funding from industry in addition to its budget from the government. The new body is in complete control of the manufacture, importation, export, distribution and sale of pharmaceuticals, food, cosmetics and medical devices.
BMI views the establishment of the FDA as a positive step, and the country’s improving regulatory environment is one reason that the Philippines’ Business Environment Rating has increased in the publisher's Q110 assessment of 15 pharmaceutical markets in the Asia Pacific region. The Philippines remains 11th in the table, with an improved score of 48.9, up from 46.6 in Q409.
Access to healthcare remains a concern in the Philippines. A study conducted by the Asian Development Bank (ADB) concluded that fewer Filipinos can afford treatment from private and government hospitals due to the high cost of medicines and healthcare services. The study showed that utilisation of healthcare in the Philippines registered an annual decline of 4.7% from 1998 to 2007. |
|
Contents: |
Executive Summary
SWOT Analysis
- Philippines Pharmaceutical And Healthcare Industry SWOT
- Philippines Political SWOT
- Philippines Economic SWOT
- Philippines Business Environment SWOT
Pharmaceutical Business Environment Ranking
- Table: Asia Pacific – Regional Pharmaceutical Business Environment Rankings For Q110
- Limits of Potential Returns
- Risks to Realisation of Returns
The Philippines – Market Summary
- Regulatory Regime
- Table: History Of Food and Drugs Administration (FDA)
- Recent Regulatory Developments
- Intellectual Property Regime
- IP Shortcomings
- IP Disputes
- Counterfeit Drugs
- Pricing And Reimbursement Regime
- Recent Pricing And Reimbursement Developments
- Parallel Trade
- International Co-operation
- Industry Trends and Developments
- Epidemiology
- Table: Top 10 Causes Of Mortality In The Philippines
- Communicable Diseases
Healthcare Sector
- Healthcare Sector Financing
- Corruption
- Medical Tourism
- Biotechnology
- Recent Biotechnology Developments
- Traditional Medicines
- Medical Devices
Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors – Industry
- Key Growth Factors – Macroeconomic
- Table: Philippines – Economic Activity, 2004-2013
- Prescription Drug Market Forecast
- Table: Top 10 Prescription Brands In The Philippines (MAT September 2007, PHPbn)
- Table: Top 20 Therapeutic Categories In The Philippines (MAT September 2007, PHPbn)
- Patented Product Market Forecast
- Generics Drug Market Forecast
- OTC Market Forecast
- Table: Top 10 OTC Brands In The Philippines (MAT September 2007, PHPbn)
- Pharmaceutical Trade Forecast
- Medical Device Market Forecasts
- Other Healthcare Data Forecasts
- Key Risks To BMI’s Forecast Scenario
Competitive Landscape
- Pharmaceutical Retail
- Table: Top 20 Leading Pharmaceutical Companies In The Philippines (PHPbn)
- Table: Comparative Growth Trend Of Foreign & Local Companies In The Philippines 2003-2007 (PHPbn)
- Table: Number Of Foreign & Local Companies Established From 2003 To 2007
Company Monitor
- Leading Multinational Manufacturers
- GlaxoSmithKline Philippines
- Pfizer
- Novartis
- Merck & Co
- Sanofi-Aventis
- Abbott Laboratories
- Bristol-Myers Squibb
- Wyeth
- Eli Lilly
- AstraZeneca
- Indigenous Manufacturers
- Unilab
- Pascual Laboratories
- Pacific Pharma Generics
- MediChem Pharmaceuticals
Country Snapshot: Philippines Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2007-2012 (US$)
- Table: Average Annual Manufacturing Wages, 2004-2006
BMI Methodology
- How The Pharmaceutical Industry Forecasts Are Generated
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources |
|
Companies Mentioned |
- GlaxoSmithKline Philippines
- Pfizer
- Novartis
- Merck & Co
- Sanofi-Aventis
- Abbott Laboratories
- Bristol-Myers Squibb
- Wyeth
- Eli Lilly
- AstraZeneca
- Unilab
- Pascual Laboratories
- Pacific Pharma Generics
- MediChem Pharmaceuticals |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/1136921
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 12/02/2012 23:38:31 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Philippines Pharmaceuticals and Healthcare Report Q1 2010
|
|
Web Address: |
http://www.researchandmarkets.com/reports/1136921
|
|
Office Code: |
|
OC8IHINLSNNSS
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (PDF)
- Single User
|
|
€398.00
|
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
Page 2 of 2
Printed 12/02/2012 23:38:31
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder's Name: |
|
|
|
|
Cardholder's Signature: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
|
|
|
|
